The relationship of the active and latent forms of TGF-β1 with marrow fibrosis in essential thrombocythemia and primary myelofibrosis

Medical Oncology

Volumn 29, Issue 4, 2012, Pages 2337-2344

  Ponce, Cesar Cilento ^a   De Lourdes F Chauffaille, Maria ^a   Ihara, Silvia Saiuli M ^a   Silva, Maria Regina R ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Active TGF 1; Essential thrombocythemia; Fibrosis; Immunohistochemistry; Latent TGF 1; Megakaryocytes; Primary myelofibrosis

Indexed keywords

RETICULIN; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; AGED; ARTICLE; BONE MARROW BIOPSY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MEGAKARYOCYTE; MYELOFIBROSIS; MYELOID METAPLASIA; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; THROMBOCYTHEMIA;

ADULT; AGED; AGED, 80 AND OVER; BONE MARROW; FEMALE; FIBROSIS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PRIMARY MYELOFIBROSIS; THROMBOCYTHEMIA, ESSENTIAL; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84868000107     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-011-0144-1     Document Type: Article

References (30)

1. Dameshek W. Some speculations on the myeloproliferative syndromes. Blood. 1951;6:372-5.
2. Foucar K. Bone Marrow Pathology. 2nd ed. Chicago: ASCP Press (American Society for Clinical Pathology); 2001.
3. Spivak JL, Siver RT. The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal. Blood. 2008;112:231-9.
4. Thiele J, Kvasnicka HM, Vardiman J. Bone marrow histopathology in the diagnosis of chronic myeloproliferative disorders: a forgotten pearl. Best Pract Res Clin Haematol. 2006;19:413-37.
5. Thiele J, Kvanicka HM, Facchetti F, Franco V, van der Walt J, Orazi A. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica. 2005;90:1128-32.
6. Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythaemia and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood. 2007;110:1092-7.
7. Kuter D, Bain B, Mufti G, Bagg A, Hasserjian R. Bone marrow fibrosis: pathophysiology and clinical significance of increased bone marrow stromal fibres. Br J Haematol. 2007;139:351-62.
8. Sporn MB, Roberts AB. Transforming growth factor-beta: recent progress and new challenges. J Cell Biol. 1992;119(5):1017-21.
9. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease. N Engl J Med. 2000;342(18):1350-8.
10. Hyytiäinen M, Penttinen C, Keski-Oja J. Latent TGF-beta binding proteins: extracellular matrix association and roles in TGF-beta activation. Crit Rev Clin Lab Sci. 2004;41:233-64.
11. Massam-Wu T, Chiu M, Choudhury R, Chaudhry SS, Valdwin AK, McGovern A, Baldock C, Shuttleworth A, Kielty CM. Assembly of fibrillin microfibrils governs extracellular deposition of Latent TGF β. J Cell Sci. 2010;123:3006-18.
12. Murphy-Ullrich JE, Poczatek M. Activation of latent TGF-β by thrombospondin -1mechanisms and physiology. Cytokine & Growth Factor Rev. 2000;11:59-69.
13. Annes JP, Munger JS, Rifkin DB. Making sense of latent TGF beta activation. J Cell Sci. 2003;116(Pt 2):217-24.
14. de Caestecker M. The transforming growth factor-beta superfamily of receptors. Cytoquine Growth Factor Rev. 2004;15(1):1-11.
15. Wakefield LM, Winokur TS, Hollands RS, Christopherson K, Levinson AD, Sporn MB. Recombinant latent transforming growth factor β 1 has a longer plasma half-life in rats than active transforming growth factor β 1, and a different tissue distribution. J Clin Investig. 1990;86:1976-84.
16. Vaughan JM, Vale WW. α2-Macroglobulin is a binding protein of inhibin and activin. Endocrinology. 1993;132:2038-50.
17. Thiele J, Hoeppner B, Zankovich R, Fischer R. Histomorphometry of bone marrow biopsies in primary osteomyelofibrosis/sclerosis (agnogenic myeloid metaplasia)correlations between clinical and morphological features. Virchows Arch A Pathol Anat Histopathol. 1989;415(3):191-202.
18. Ciurea SO, Merchant D, Mahmud N, Ishii T, Zhao Y, Hu W, Bruno E, Barosi G, Xu M, Hoffman R. Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis. Blood. 2007;110(3):986-93.
19. Dong M, Blobe GC. Role of transforming growth factor-β in hematologic malignancies. Blood. 2006;107(12):4589-96.
20. Bain BJ, Clark DM, Lampert IA, Wilkins BS. Bone marrow pathology. London: Blackwell; 2001.
21. Gomori G. Silver impregnation of reticulum in paraffin sections. Am J Pathol. 1937;13:993-1001.
22. Gomori G. The effect of certain factors on the results of silver impregnation for reticulum fibers. Am J Pathol. 1939;15:493-5.
23. van der Woude CJ, Kleibeuker JH, Tiebosch ATGM, Homan M, Beuving A, Jansen PLM, Moshage HJ. Diffuse and intestinal type gastric carcinomas differ in their expression of apoptosis related proteins. J Clin Pathol. 2003;56:699-702.
24. Ponce CC, Chauffaille MLF, Ihara SSM, Silva MRR. MPL immunohistochemical expression as a novel marker for essential thrombocythemia and primary myelofibrosis differential diagnosis. Leuk Res. 2012;36(1):93-7.
25. Kuroda H, Matsunaga T, Terui T, et al. Decrease of Smad 4 gene expression in patients with essential thrombocythaemia may cause an escape from suppression of megakaryopoiesis by transforming growth factorbeta 1. Br J Haematol. 2004;124:211-20.
26. Chagraoui H, Komura E, Tulliez M, Giraudier S, Vainchenker W, Wendling F. Prominent role of TGF-beta 1 in thrombopoietin-induced myelofibrosis in mice. Blood. 2002;100:3495-503.
27. Bock O, Loch G, Schade U, Wasielewski von R, Schlué J, Kreipe H. Aberrant expression of transforming growth factor B-1 (TGFB-1) per se does not discriminate fibrotic from non-fibrotic chronic myeloproliferative disorders. J Pathol. 2005;205:548-57.
28. Yoon SY, Tefferi A, Li CY. Cellular distribution of platelet-derived growth factor, transforming growth factor beta, basic fibroblast growth factor, and their receptors in normal bone marrow. Acta Haematol. 2000;104(4):151-7.
29. Taipale J, Saharinen J, Hedman K, Keski-Oja J. Latent transforming growth factor-beta 1 and its binding protein are components of extracellular matrix microfibrilschem. J Histo Cytochem. 1996;44:875-89.
30. Dallas SL, Sivakumar P, Jones CJ, Chen Q, Peters DM, Mosher DF, Humphries MJ, Kielty CM. Fibronectin regulates latent transforming growth factor-beta (TGF beta) by controlling matrix assembly of latent TGF beta-binding protein-1. J Biol Chem. 2005;280:18871-80.